Phase 2 Study of Interferon Alfa-2b and Lovastatin Combination Therapy for Patients With High-risk Resected or Unresectable Malignant Melanoma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Interferon alpha-2b; Lovastatin
- Indications Malignant melanoma
- Focus Therapeutic Use
Most Recent Events
- 10 Sep 2009 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 10 Sep 2009 Planned end date changed from 1 Sep 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov.
- 10 Sep 2009 Actual initiation date (Dec 2009) added as reported by ClinicalTrials.gov.